All In Biotech

Drug Trial Radar · NCT04762758

Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients

A Multi-center, Randomized, Double-blind, Placebo Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A)

Last checked: Nov 19, 2026Latest source record: Apr 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

350

Planned (sponsor's estimate)

Start

Mar 30, 2021

Primary completion

Apr 19, 2024

Study completion Apr 19, 2024

Sponsor

Lead sponsor
Pharnext S.C.A.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Worldwide Clinical Trials
First posted
Feb 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will consist of 2 periods: Double-blind Treatment and Open-Label Extension(OLE) Period. -Double-blind Treatment Period - This will be randomized, double-blind, placebo-controlled part of the study which will be conducted in parallel groups, ie,1 group receiving the active treatment (PXT3003) and the other group receiving placebo. Primary endpoint of the study will be assessed at Month 15. -Open-label Extension (OLE) Period - All subjects completing Double-blind Treatment Period will be given an opportunity to enter the OLE Period of the study and receive the active treatment (PXT3003). The duration of the OLE Period will be based on Sponsor discretion, ie, Sponsor intends to keep the study open until the study drug PXT3003 is commercially available. During this period, the long-term safety and efficacy of PXT3003 will be assessed as an exploratory objective. Double-blind Treatment Period Objectives: Primary: To evaluate the efficacy of treatment with PXT3003 (a fixed-dose combination of \[RS\]-baclofen, naltrexone hydrochloride \[HCl\], and D-sorbitol) compared to placebo in subjects with Charcot-Marie-Tooth disease type 1A (CMT1A). Secondary: To evaluate the safety and tolerability of PXT3003 treatment in subjects with CMT1A. Exploratory: To characterize the relationship between plasma biomarkers and response to PXT3003 treatment. OLE Period Objective: Exploratory: To evaluate the long-term safety and efficacy of PXT3003.

Conditions

  • Charcot-Marie-Tooth Disease

Interventions

  • (RS)-baclofen, naltrexone hydrochloride and D-sorbitolDrug

    oral fixed dose combination

  • PlaceboDrug

    liquid oral solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. modified Overall Neuropathy Limitation Scale (mONLS)Time frame: From Baseline to Month 15

Locations

50 sites in 9 countries. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • UCLA Department of Psychiatry and Biobehavioral Sciences

    Los Angeles, California

  • UC Davis Health Department of Physical Medicine and Rehabilitation

    Sacramento, California

  • Hospital for Special Care

    New Britain, Connecticut

  • University of Florida Clinical Research Center

    Gainesville, Florida

  • University of Miami Leonard M. Miller School of Medicine

    Miami, Florida

  • Advent Health Medical Group Neurology Orlando

    Orlando, Florida

  • University of Kansas Medical Center Research Institute

    Fairway, Kansas

  • Massachusetts General Hospital Neuromuscular Diagnostic Center

    Boston, Massachusetts

  • University of Minnesota Health

    Minneapolis, Minnesota

  • MU Health Care Neurology and Sleep Disorders Clinic

    Columbia, Missouri

  • Hackensack Meridian Health Hackensack University Medical Center

    Hackensack, New Jersey

  • Colombia University Department of Neurology

    New York, New York

  • UNC Department of Neurology Peripheral Neuropathy Center

    Chapel Hill, North Carolina

  • Atrium Health Neurosciences Institute

    Charlotte, North Carolina

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • Oregon Neurology

    Springfield, Oregon

  • National Neuromuscular Research Institute

    Austin, Texas

  • Neurology Clinic at University of Washington Medical Center

    Seattle, Washington

  • Providence St. Luke's Rehabilitation Medical Center

    Spokane, Washington

  • Universitaire Ziekenhuizen Leuven

    Leuven, Belgium

  • Ottawa Hospital Research Institute- Neuromuscular Research Centre

    Ottawa, Ontario, Canada

  • UHN Toronto General Hospital Krembil Neuroscience Centre

    Toronto, Ontario, Canada

  • CIUSS de Saguenay-Lac-Saint-Jean Centre d'etudes Cliniques

    Chicoutimi, Quebec, Canada

  • Montreal Neurological Institute and Hospital-Clinical Research Unit

    Montreal, Quebec, Canada

  • CHU de Quebec-Universite Laval- Hopital Enfant-Jesus

    Québec, Quebec, Canada

  • Rigshospitalet, University of Copenhagen Copenhagen Neuromuscular Center

    Copenhagen, Denmark

  • Centre de Reference des Maladies Neuromusculaires AOC Service de Neurologie, CHU d'Angers

    Angers, France

  • Centre de reference des maladies neuromusculaires AOC Hopital Pellegrin CHU de Bordeaux

    Bordeaux, France

  • CHU de Lille Hôpital Salengro

    Lille, France

  • Service de Neurologie et Maladies Neuromusculaires, CHU de Marseille - Hopital La Timone

    Marseille, France

  • Association lnstitut de Myologie Hopital Pitie-Salpetriere Service de Neuro-Myologie

    Paris, France

  • Centre d'investigation Clinique CHU de Strasbourg Hopital de Hautepierre

    Strasbourg, France

  • University Hospital RWTH Aachen, Department of Neurology and Institute for Neuropathology

    Aachen, Germany

  • University Medical Centre Goettingen, Dept. of Clinical Neurology

    Göttingen, Germany

  • Friedrich-Baur-Institut, Neurologische Klinik und Poliklinik Ludwig-Maximilians-Universität

    München, Germany

  • University Hospital Muenster UKM Department of Neurology

    Münster, Germany

  • Universitätsklinikum Tübingen Crona Kliniken Neuromuskuläres Zentrum

    Tübingen, Germany

  • Hadassah Ein Kerem University Medical Center Department of Neurology

    Jerusalem, Israel

  • Sheba Medical Center

    Ramat Gan, Israel

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.